Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases

Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen. Nevertheless, one third of estrogen receptor positive breast cancer patients initially do not respond to endocrine therapy and about 40% of lu...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Sommer, Ann-Katrin, Hermawan, Adam, Mickler, Frauke Martina, Ljepoja, Bojan, Knyazev, Pjotr, Bräuchle, Christoph, Ullrich, Axel, Wagner, Ernst, Roidl, Andreas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2016
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226596/
https://ncbi.nlm.nih.gov/pubmed/27409163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10459
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items